In a recent press announcement, The U.S. National Institutes of Health (NIH) has agreed to invest in the development of gene therapies in an attempt to cure HIV and sickle cell diseases. The program, for which NIH will partner with The Bill & Melinda Gates Foundation, will involve funding of $100 million each over the next four years.
Agenda of the partnership: One of the prime objectives of the partnership is to make the therapies affordable and accessible to people around the world. The focus is primarily on developing countries, where the burden of these diseases is the greatest.
When can we expect the drug: While drug development is a highly uncertain domain, as per the agency, the therapy will mostly be ready for testing in clinical trials in the US and sub-Saharan Africa within the next seven to 10 years.
Read the complete coverage here.
Who else is developing gene therapies for Infectious Diseases: There are a number of companies that are currently developing gene therapies for infectious diseases. As per the recent gene therapy market report by Roots Analysis, there are close to 35 candidates already in development for the treatment of infectious diseases.
How big is the gene therapy pipeline for HIV: Given the high treatment burden, HIV remains one of the key focus areas of the gene therapy developers in the infectious disease space. Below, I have added a quick snapshot of the gene therapy pipeline for HIV.
How big is the gene therapy market: The overall gene therapy market is expected to reach close to $12 billion by 2030.
For detailed insights about the gene therapies market, check out the report here.